Kentucky Retirement Systems Reduces Position in Becton, Dickinson and Company (NYSE:BDX)

Kentucky Retirement Systems lowered its holdings in Becton, Dickinson and Company (NYSE:BDXFree Report) by 1.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 23,212 shares of the medical instruments supplier’s stock after selling 425 shares during the period. Kentucky Retirement Systems’ holdings in Becton, Dickinson and Company were worth $5,660,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of BDX. Vanguard Group Inc. boosted its holdings in shares of Becton, Dickinson and Company by 2.0% in the third quarter. Vanguard Group Inc. now owns 25,927,519 shares of the medical instruments supplier’s stock worth $6,703,041,000 after acquiring an additional 516,427 shares during the period. Morgan Stanley boosted its stake in Becton, Dickinson and Company by 4.5% in the 3rd quarter. Morgan Stanley now owns 10,200,213 shares of the medical instruments supplier’s stock worth $2,637,062,000 after purchasing an additional 435,168 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in Becton, Dickinson and Company by 11.0% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,192,832 shares of the medical instruments supplier’s stock valued at $1,342,503,000 after buying an additional 512,566 shares in the last quarter. Ameriprise Financial Inc. increased its position in shares of Becton, Dickinson and Company by 9.2% during the third quarter. Ameriprise Financial Inc. now owns 3,630,351 shares of the medical instruments supplier’s stock valued at $938,593,000 after buying an additional 304,629 shares during the period. Finally, Clearbridge Investments LLC increased its position in shares of Becton, Dickinson and Company by 2.9% during the third quarter. Clearbridge Investments LLC now owns 3,135,238 shares of the medical instruments supplier’s stock valued at $810,553,000 after buying an additional 89,714 shares during the period. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX traded down $0.32 on Friday, hitting $236.30. The company’s stock had a trading volume of 1,785,047 shares, compared to its average volume of 1,436,944. The company has a market capitalization of $68.29 billion, a PE ratio of 52.05, a PEG ratio of 2.07 and a beta of 0.45. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.41 and a quick ratio of 0.97. The company has a 50-day simple moving average of $238.15 and a 200 day simple moving average of $239.03. Becton, Dickinson and Company has a 1 year low of $229.40 and a 1 year high of $287.32.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last announced its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.97 by $0.20. The company had revenue of $5.05 billion during the quarter, compared to analyst estimates of $5.04 billion. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The firm’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the previous year, the business earned $2.86 earnings per share. Sell-side analysts forecast that Becton, Dickinson and Company will post 13.04 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 10th will be given a dividend of $0.95 per share. The ex-dividend date is Monday, June 10th. This represents a $3.80 annualized dividend and a dividend yield of 1.61%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 83.70%.

Insider Activity

In related news, EVP Michael David Garrison sold 1,715 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total value of $399,269.15. Following the completion of the sale, the executive vice president now owns 5,381 shares in the company, valued at approximately $1,252,750.61. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, EVP Michael David Garrison sold 1,715 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total value of $399,269.15. Following the transaction, the executive vice president now owns 5,381 shares in the company, valued at approximately $1,252,750.61. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Thomas J. Spoerel sold 282 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $238.29, for a total transaction of $67,197.78. Following the sale, the senior vice president now owns 2,276 shares of the company’s stock, valued at $542,348.04. The disclosure for this sale can be found here. In the last three months, insiders have sold 8,597 shares of company stock worth $2,028,786. 0.31% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Separately, Barclays boosted their price objective on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a research note on Monday, May 6th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $281.40.

Read Our Latest Report on BDX

Becton, Dickinson and Company Profile

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

See Also

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXFree Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.